韓国の製薬GL RaphaがスプートニクV コロナウイルスワクチン製造ライセンス契約を締結

Russia deals with South Korean pharmaceutical GL Rapha to manufacture Sputnik V coronavirus vaccine

The Russian Direct Investment Fund (RDIF) and Seoul-based pharmaceutical company GL Rapha have signed a deal to produce more than 150 million doses of Russia’s Sputnik V Covid-19 vaccine in South Korea annually.

Production will begin in December and the vaccine will be exported to countries around the world starting in January 2021.

The first interim results of a large-scale Phase III clinical trial for the jab were released earlier this week and showed 92-percent efficacy. Researchers said they would publish their preliminary findings in a top medical journal and promised to make available a full clinical trial report once the testing phase is complete. They said it would take up to six months to ensure that participants in the trials do not suffer any side effects.

Developed by Russia’s Gamaleya Research Institute of Epidemiology and Microbiology, Sputnik V is the world’s first registered Covid-19 vaccine. It is now undergoing the Phase III clinical trial involving 40,000 volunteers.

Other countries are also taking part in testing the vaccine. Belarus, the UAE, Venezuela, and India are conducting their own clinical trials of Sputnik V, and could potentially purchase doses, or licensing rights to produce the vaccine, for domestic distribution.

ロシアは韓国の製薬GL RaphaとスプートニクVコロナウイルスワクチンを製造するために取引する

ロシア直接投資基金(RDIF)とソウルの製薬会社GL Raphaは、ロシアのスプートニクVコビド-19ワクチンを韓国で年間1億5000万回分以上生産する契約を締結した。






Russia & Hungary consider JOINT production of Sputnik V coronavirus vaccine
Budapest is set to receive its first samples of the Sputnik V vaccine next week, Russia’s industry and trade ministry has said, revealing that the two countries are considering joint, Hungarian-based production of the shots.

The announcement was made on Friday following talks between Russian Industry and Trade Minister Denis Manturov and Hungarian Foreign Minister Peter Szijjarto.

Manturov confirmed that the first batch of vaccine samples will be delivered next week, while Szijjarto said that the Hungarian government has decided to simplify the process of certification for medical products, citing the urgency of the coronavirus situation.

Moreover, the two countries are considering launching joint production of the vaccine.

“A respective production site is currently being prepared in Hungary. Thus, Hungary may become the first country in the European Union to begin the production of the Russian vaccine,” the ministry said in a statement.

Budapest first revealed it was in talks with Russia and China over procuring a Covid-19 vaccine late in October. The move has put additional pressure on the already strained relations between Hungary and the EU. The EU Commission warned Budapest that only EU-approved Covid-19 vaccines will be certified for use by member states and threatened Hungary with repercussions.

Hungary has defied the EU’s threats, however, insisting it has the right to procure whatever vaccine it pleases. Speaking to RT earlier this week, Szijjarto said Budapest “will not allow anybody to put pressure on us not to negotiate with eastern counterparts,” and even dismissed what he called a “rumor” that EU member states are unable to buy vaccines from outside the bloc as “absolutely not true.”

The minister also called upon countries worldwide to cooperate in wake of the pandemic, instead of “over-politicizing” the vaccines issue and attacking each other.

“The more vaccines the better,” Szijjarto said, explaining that the country was open to purchasing any working vaccines, regardless of where they were produced.

Compared to other European nations, Hungary has been relatively spared by the pandemic so far, registering some 130,000 cases and around 2,800 deaths.

That figure is still quite sizable for the 9.8 million nation, though, and it has recently experienced a surge in new daily cases.

Hungarian PM Viktor Orban warned on Monday that unless anti-coronavirus action is taken swiftly, the country’s healthcare system might get overwhelmed with the flow of new patients.

“If the number of people infected increases at such a rate, hospitals will not be able to cope with the burden on them, so the number of illnesses will have to be reduced; mask-wearing is no longer enough. Restrictive measures are needed,” Orban said, adding that while the vaccine relief was close, it was still several weeks away.



大臣はまた、ワクチン問題を "過剰に政治化 "してお互いを攻撃するのではなく、パンデミックをきっかけに協力するよう世界各国に呼びかけた。

"より多くのワクチンより良い、"Szijjarto は言った、国は、彼らが生産された場所に関係なく、任意の作業ワクチンを購入するオープンだったことを説明します。

他のヨーロッパ諸国と比較して、ハンガリーはこれまでのところ、いくつかの 130,000 ケースと約 2,800 の死を登録するパンデミックによって比較的免れています。




posted by ZUKUNASHI at 16:41| Comment(0) | Covid19


※ Eric Feigl-Ding@DrEricDing氏の2020/11/12のツイート
2) In a followup survey of 488 #COVID19 patients post discharge, Cardiopulmonary symptoms (such as cough and dyspnea) were reported by 159 patients or 32.5%, including ***92 (19%) with new or worsening symptoms*** and 65 with persistent loss of taste or smell.

※ Eric Feigl-Ding@DrEricDing氏の2020/11/12のツイート
3) Of the 117 patients who returned to work, 30 reported reduced hours or modified duties due to health reasons. That is **1 in 4 people** who couldn’t fully work−among those who even could post #COVID19 hospital discharge.

※ Eric Feigl-Ding@DrEricDing氏の2020/11/12のツイート
4) Nearly half of all patients (238 of 488) reported being emotionally affected by their health.

※ Eric Feigl-Ding@DrEricDing氏の2020/11/12のツイート
5) Moreover, 179 patients reported at least a mild financial impact from their hospitalization
47 reporting use of most or all of their savings and 35 rationing food, heat, housing, or medications due to cost.

※ Eric Feigl-Ding@DrEricDing氏の2020/11/12のツイート
6) Summary− “These data confirm that the toll of COVID-19 extends well beyond hospitalization. Although most patients saw a primary care provider after discharge, 1 in 5 had no primary care follow-up visit within 60 days of discharge.

※ Eric Feigl-Ding@DrEricDing氏の2020/11/12のツイート
7) BOTTOMLINE: Collectively, these findings suggest that better models to support COVID-19 survivors are necessary. This is why we need @Survivor_Corps led by @dianaberrent
結論: これらの知見をまとめると、COVID-19の生存者を支援するためのより良いモデルが必要であることが示唆される。これが、@dianaberrentが率いる@Survivor_Corpsが必要な理由です。

※ Eric Feigl-Ding@DrEricDing氏の2020/11/12のツイート
8) And we need to stop this coronavirus. We do not want this to be our continued fate. #COVID19
私たちは、コロナウイルスを止める必要があります これが私たちの引き続く運命であって欲しくありません。

※ Eric Feigl-Ding@DrEricDing氏の2020/11/12のツイート
Horrifying: New single-day all time high 144k US cases of #COVID19. All time high 65.4k COVID patients hospitalized. And >1500 deaths in single day, highest since May. Death lag is ~3 weeks. December will be horrendous.
CHOOSE WISELY: Do we want 406x the cases in 60 days?

※ Hiroshi Tsuji@Hiroshi_Tsuji氏の2020/11/13のツイート
posted by ZUKUNASHI at 14:41| Comment(0) | Covid19








posted by ZUKUNASHI at 12:10| Comment(0) | Covid19